Nick Talbot

34.3K posts

Nick Talbot banner
Nick Talbot

Nick Talbot

@talbotlabTSL

Interested in plant pathology, fungal development, cell biology. I study a disease called rice blast. Executive Director, The Sainsbury Laboratory- Views my own

England, United Kingdom Katılım Mayıs 2010
1.7K Takip Edilen11.4K Takipçiler
Nick Talbot
Nick Talbot@talbotlabTSL·
Irises this morning
Nick Talbot tweet media
English
0
1
21
289
Nick Talbot retweetledi
Isomorphic Labs
Isomorphic Labs@IsomorphicLabs·
Today marks a pivotal moment for Isomorphic Labs. We have secured $2.1 Billion in our second external funding round, led by Thrive Capital. They are joined at the table by Alphabet, GV and new investors MGX, Temasek, CapitalG and the UK Sovereign AI Fund. This milestone accelerates our ability to build the pioneering novel AI models that power our AI drug design engine (IsoDDE) and deploy them at scale: delivering scientific breakthroughs with a precision previously thought impossible, accelerating and expanding our pipeline of therapeutic programs toward the clinic. All with the ultimate goal of delivering life-changing new medicines to patients. Moving forward, we will scale our drug candidate pipelines across multiple therapeutic areas, expand our global footprint, and push the boundaries of frontier AI research to power our drug design engine. Deeply grateful to everyone sharing our vision to solve all disease with AI. Let’s build the future of medicine. Read the full announcement here: bit.ly/4v2OI03
English
55
221
1.9K
256.1K
Nick Talbot retweetledi
Natasha Malpani 👁
Natasha Malpani 👁@natashamalpani·
isomorphic labs just raised $2.1 billion. no human patient has been dosed yet. the first clinical trials are expected end of 2026. zasocitinib just cleared Phase 3. the first AI-designed drug to do it. zasocitinib was discovered by nimbus therapeutics using @schrodinger's physics-based simulation platform. the model understood molecular interactions from first principles. it validates one specific thesis: AI works in biology when the search space is large, the functional assay is clear, and you can close the loop between model and experiment. @IsomorphicLabs’ bet is that this same first-principles approach scales across the entire drug discovery stack. multiple therapeutic areas. multiple modalities. from structure prediction all the way to the clinic. zasocitinib is the closest validation point this thesis has ever had. it is also a reminder that one layer working does not mean the whole stack works. the 90% Phase 2/3 failure rate has not moved. the virtual cell is unproven. the hardest layers are still ahead. biology does not digitise uniformly. zasocitinib is the first proof. isomorphic is the next wager.
English
8
16
174
20.3K
Nick Talbot retweetledi
altan tutar
altan tutar@altantutar·
"You can't build a startup in London. You have to move to SF." Imagine still believing this in 2026??? London AI startups raised $5.65bn last quarter alone. Recursive just launched today with $650m to build safe self-improving AI. The SECOND nine-figure London AI launch this month. Two UCL professors just led two of Europe's largest-ever AI funding rounds. Over the last quarter: 1/ @nscale, $2bn at $14.6bn, AI hyperscaler (largest funding round in European history) 2/ @wayve_ai, $1.2bn at $8.6bn, self-driving foundation models 3/ Ineffable Intelligence, $1.1bn seed at $5.1bn, superintelligence via reinforcement learning (largest seed in European history) 4/ @recursive_si, $650m at $4.65bn, AI that experiments on how to safely improve itself 5/ @elevenlabsio, $500m at $11bn, frontier AI voice 6/ @synthesiaIO, $200m at $4bn, AI video UK is building chips too: 7/ @graphcoreai, $457m from SoftBank 8/ Fractile, in talks for ~$200m at £800m LETS GO!
etn.@etnshow

BREAKING: University College London Professor Tim Rocktäschel officially launches Recursive with $650M in funding at a $4.65B valuation led by Google Ventures.

English
21
22
117
18.5K
Nick Talbot retweetledi
Seb Johnson
Seb Johnson@SebJohnsonUK·
A UK Chip startup has JUST raised $220m to take on Nvidia! @AnthropicAI is already looking to buy chips from them. There have been rumours about the round for some time, but it has now been confirmed. @fractile_ai has raised a $220m Series B led by @Accel, @foundersfund and @factorialfunds. Its chips rely on a different kind of memory technology to Nvidia’s GPUs called static random access memory (SRAM). This is to improve the speed and cost of AI inference. The raise follows another big UK Chip raise - Olix which raised $220m at a $1bn valuation. Two years ago it would have been unimaginable to have two UK unicorns become unicorns by trying to take on Nvidia, and yet here we are. LETS GO
English
4
6
85
15.9K
Nick Talbot retweetledi
Martin Bauer
Martin Bauer@martinmbauer·
UK universities are among the country’s most successful institutions. The fact that successive governments have maintained a fundamentally unsustainable funding model, forcing universities into a slow-motion financial crisis, will go down as a failure of historic proportion
Jonathan Birch@birchlse

UK universities are miraculous. A case in point is the University of Sheffield, which has a total endowment of £59m (about 21x Princeton's per-student endowment) and 6 Nobel prizes. We're losing one of the most cost-effective research juggernauts on Earth.

English
14
61
261
20.6K
Nick Talbot retweetledi
Sophien Kamoun
Sophien Kamoun@KamounLab·
Agentic AI is really taking off. Today Claude cowork attended our meeting by itself. 🔥
Sophien Kamoun tweet media
English
2
2
32
1.4K
Nick Talbot retweetledi
Tatsuya Nobori
Tatsuya Nobori@nobolly·
We are excited to welcome Ketil Krabbe as a new pre-doc in our group at @TheSainsburyLab. Ketil completed his master’s with Sarah O’Connor at MPI Jena (single-cell metabolomics) and a science policy internship at @OPCW before joining us. Welcome, Ketil!
Tatsuya Nobori tweet mediaTatsuya Nobori tweet media
English
0
4
43
3.1K
Nick Talbot retweetledi
Demis Hassabis
Demis Hassabis@demishassabis·
I’ve always believed the No.1 application of AI should be to improve human health. That work started with AlphaFold, and now at @IsomorphicLabs with the mission to reimagine drug discovery and one day solve all disease! We are turbocharging that goal with $2.1B in new funding.
English
657
2.4K
19.3K
2.8M
Nick Talbot retweetledi
Seb Johnson
Seb Johnson@SebJohnsonUK·
IT'S OFFICIAL. Isomorphic Labs has raised $2.1bn led by Thrive Capital. The round includes Alphabet, Abu Dhabi’s MGX, Singapore’s Temasek and OF COURSE the UK’s Sovereign AI fund (@UKSovereignAI). The company has started pre-clinical trials, which @demishassabis has said are “going very well, and we’re on track,”. No valuation given, any guesses from those who know biotech better?
Bloomberg@business

DeepMind Spinout Isomorphic Labs Raises $2.1 Billion to Design Drugs With AI bloomberg.com/news/articles/…

English
3
4
40
4.1K
Nick Talbot retweetledi
Seb Johnson
Seb Johnson@SebJohnsonUK·
A UK startup has just raised one of the largest rounds in Biotech history. $2.1bn raised to use AI to create new drugs and cure diseases. Spun out of @GoogleDeepMind, headed up by @demishassabis, and now backed by the UK's @UKSovereignAI fund. And of course headquartered in LONDON. Amazing news - congrats @IsomorphicLabs
English
15
45
373
33.3K
Nick Talbot retweetledi
AmirAli Toghani
AmirAli Toghani@amiralito_·
Protein structure prediction changed biology. Protein assembly discovery is next. We present SNI (Structural Novelty Index), a scalable framework for finding new protein complexes. We used it to uncover an unexpected resistosome assembly: 11-mer. 🧵👇🏻 biorxiv.org/content/10.648…
AmirAli Toghani tweet media
English
3
74
219
43.6K
Nick Talbot retweetledi
Channel 4 News
Channel 4 News@Channel4News·
Hope for Britain’s Ash trees thanks to scientific ‘eureka’ moment Scientists at the John Innes Centre in Norwich have found a way to speed up the germination of seeds, allowing disease-resistant Ash trees to grow, writes @alextomo Read our latest newsletter here: channel4news.substack.com/p/hope-for-bri…
Channel 4 News tweet media
English
0
244
794
30.4K
Nick Talbot retweetledi
Nick Desnoyer
Nick Desnoyer@NickDesnoyer·
The beauty of nature is a universal motivation for first getting into Biology, yet is largely undervalued once in the lab. Great thread by Niko on how bioengineering beauty can have real applications for fundamental research and education 🙌
Niko McCarty.@NikoMcCarty

Beauty should be a core pursuit of biotechnology. There should be companies and nonprofits that engineer organisms solely for the sake of crafting beautiful things. A few reasons why: 1/ Biotechnology has historically worked in reductionist ways, but many useful functions only emerge at the systems level. By engineering a systems-level outcome, like beauty, we will get much better at engineering organisms in predictable ways. When I say "reductionist," I mean that most useful things in biotechnology (drugs and tools) were discovered by stripping molecules from their natural contexts. Scientists collect organisms from soil or wherever and then study their molecules in isolation. This basic approach has yielded everything from rapamycin to antibiotics and CRISPR. This reductionism, though, means that that we know disturbingly little about how life actually works at a systems-level. My core argument is that, by studying beauty, we can remedy this. Beauty has persisted through tens of millions of years of evolution because it is functional; bright colors help attract pollinators to a plant, for example, which helps the plant breed. If evolution has created all of this beauty for functional reasons, then it stands to reason that by trying to create **new** forms of beauty, we'll be able to discover and understand how these systems-level functions work! Indeed, we may even be able to create entirely new functions that biology hasn't evolved yet. These functions will not possible to understand via isolated molecules or reductionism. Therefore, a company pursuing engineered beauty for the sake of beauty will probably make many fundamental discoveries about how organisms develop, interact, adapt to their surroundings, and so on. 2/ Beauty is a way to grow the field and bring more people into biotechnology. Nick Desnoyer’s flower design work, for example, has probably reached hundreds of thousands of people. The glowing plants from Light Bio, too, were featured in the mainstream press. You may not think that these examples are “important” for the universe relative to, say, an incrementally better cancer therapeutic, but there’s no question that they are way more popular to mainstream audiences and good, overall, for the field. 3/ The market is huge! Breeding is already widely used to engineer beauty, or at least to select for aesthetic preferences. Pugs are evolutionarily suboptimal, but they've been bred precisely to satisfy a certain aesthetic desire are now a multi-billion dollar industry. The Juliet Rose, developed via breeding over a 15-year period, debuted at the 2006 Chelsea Flower Show and is enormously profitable today. Why should deliberately engineered forms of beauty be any different? If you are building a biotech company or nonprofit that is pursuing beauty, please reach out! I’d love to help.

English
0
12
68
3.6K
Nick Talbot
Nick Talbot@talbotlabTSL·
Today our group hosted Sierra Cole from the laboratory of Amy Gladfelter at Duke - talking about the fascinating biology of RNA-binding proteins and condensate formation @TheSainsburyLab
Nick Talbot tweet media
English
0
1
22
1K
Nick Talbot
Nick Talbot@talbotlabTSL·
Great talk today from Gary Ruvkun - a tour de force through microRNA biology and some fascinating insights into tRNA modifications and their potential biological function. Amazing @TheSainsburyLab
Nick Talbot tweet media
English
1
6
32
2.7K